Literature DB >> 11179779

Localization of NK1 and NK3 receptors in guinea-pig brain.

J Yip1, L A Chahl.   

Abstract

In this study the localizations of tachykinin neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors in the guinea-pig brain are described. In agreement with studies in rat and human brain, the neurons that exhibited the most marked NK1 receptor immunoreactivity were found in the dorsomedial caudate putamen. NK1 receptors were also widely distributed in diencephalic structures and in the mid and hind brain. NK3 receptors were distributed in both superficial and deep layers of the cortex and many appeared to be located on cells with astrocyte-like morphology in the glia limitans. In several regions including the thalamus, hypothalamus, amygdala, periaqueductal gray, substantia nigra and area postrema, both NK1 and NK3 immunoreactivity were found. The present study revealed that tachykinin receptors are widely distributed in the guinea-pig central nervous system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179779     DOI: 10.1016/s0167-0115(00)00228-7

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  15 in total

1.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

2.  Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway.

Authors:  Geoffrey M Drew; Benjamin K Lau; Christopher W Vaughan
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

3.  Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva).

Authors:  Andrew P Ray; Seetha Chebolu; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2009-08-21       Impact factor: 3.533

4.  Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.

Authors:  Nissar A Darmani; Yaozhi Wang; Joseph Abad; Andrew P Ray; Gerald R Thrush; Juan Ramirez
Journal:  Brain Res       Date:  2008-04-09       Impact factor: 3.252

5.  Neurokinin-1 receptors in cholinergic neurons of the rat ventral pallidum have a predominantly dendritic distribution that is affected by apomorphine when combined with startle-evoking auditory stimulation.

Authors:  E Mengual; J Chan; D Lane; M San Luciano Palenzuela; Y Hara; A Lessard; V M Pickel
Journal:  Neuroscience       Date:  2007-12-04       Impact factor: 3.590

6.  Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.

Authors:  Andrew P Ray; Seetha Chebolu; Juan Ramirez; Nissar A Darmani
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

Review 7.  Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome.

Authors:  Geoffrey Littlejohn
Journal:  Nat Rev Rheumatol       Date:  2015-08-04       Impact factor: 20.543

8.  Neurokinin 3 receptor immunoreactivity in the septal region, preoptic area and hypothalamus of the female sheep: colocalisation in neurokinin B cells of the arcuate nucleus but not in gonadotrophin-releasing hormone neurones.

Authors:  M Amstalden; L M Coolen; A M Hemmerle; H J Billings; J M Connors; R L Goodman; M N Lehman
Journal:  J Neuroendocrinol       Date:  2009-11-14       Impact factor: 3.627

9.  Nicotine enhances excitability of medial habenular neurons via facilitation of neurokinin signaling.

Authors:  Dang Q Dao; Erika E Perez; Yanfen Teng; John A Dani; Mariella De Biasi
Journal:  J Neurosci       Date:  2014-03-19       Impact factor: 6.167

10.  Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Authors:  Judith A Siuciak; Sheryl A McCarthy; A N Martin; D S Chapin; J Stock; D M Nadeau; S Kantesaria; D Bryce-Pritt; S McLean
Journal:  Psychopharmacology (Berl)       Date:  2007-06-10       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.